Second Harmonic Generation Screening for Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying allosteric modulators are laborious and inefficient, as they require sorting through numerous potential drug candidates to distinguish between competitive inhibitors, non-competitive inhibitors, and allosteric modulators, with conventional screening techniques often producing ambiguous results due to nonspecific binding.
Innovation Solution
A method involving a library of candidate biochemical entities with a common scaffold core, where conformational changes in intrinsically disordered proteins are measured using second harmonic generation (SHG) to generate signatures, allowing for the selection of drug candidates based on signal differences indicative of improved pharmacological properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional screening techniques are used to identify allosteric modulators, then a large number of potential drug candidates can be tested, but the process becomes laborious and produces ambiguous results due to nonspecific binding
Solution Approach 1:
The patent replaces conventional mechanical/chemical binding assays with second harmonic generation (SHG), an optical technique that detects conformational changes in proteins. This substitution allows for more precise and specific detection of allosteric modulator binding, eliminating the ambiguity of nonspecific binding results while maintaining the ability to screen large numbers of candidates
Solution Approach 2:
The patent utilizes optical signal changes (second harmonic generation signals) to detect and differentiate between specific binding events and nonspecific binding. The SHG technique produces measurable signal changes that correspond to conformational changes in the target protein, providing clear, unambiguous detection of true positives among the large pool of candidates
2Reliability
If conventional activity assays are used to identify allosteric modulators, then binding can be detected, but the mechanism of action becomes laborious to determine
Solution Approach 1:
The patent replaces time-consuming multi-protein activity assays with a direct optical measurement technique (SHG) that detects conformational changes in the target protein's binding pocket. This substitution provides reliable binding detection while dramatically reducing the time required to determine mechanism of action, as the technique directly measures the structural change without requiring complex functional assays
3Adaptability or versatility
If conventional screening is used to sort inhibitors, then candidates can be evaluated, but the complexity of distinguishing between competitive, non-competitive, and allosteric modulators increases
Solution Approach 1:
The patent replaces complex multi-step sorting procedures with a single optical measurement technique (SHG) that directly detects conformational changes. This substitution simplifies the entire screening process, allowing simultaneous evaluation of competitive, non-competitive, and allosteric modulators through their distinct conformational effects, thereby reducing device complexity while maintaining comprehensive evaluation capability
Solution Approach 2:
The patent uses distinct optical signal patterns (second harmonic generation signals) to differentiate between various types of inhibitors. Each inhibitor type produces a characteristic signal pattern corresponding to its specific binding mode and conformational effect, enabling easy distinction and classification without complex analytical procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient screening of drug candidates by distinguishing between candidates with improved pharmacological properties through measurable conformational changes, reducing the complexity of identifying effective allosteric modulators.
Implementation Method 1
measuring a first conformational state of an intrinsically disordered protein, thereby generating a baseline; measuring a second conformational state of the intrinsically disordered protein... the measuring steps comprise measurements of second harmonic generation (SHG)
Data Source
Figure 1A~1E
Figure 2A~2B
Figure 2C
AI summary
Described herein are methods useful for screening candidate biochemical entities targeting a target biochemical entity and methods useful for identifying a binding moiety for a target biochemical entity. The invention provides methods of screening drug candidates targeting a target biomolecule, comprising selecting a drug candidate based on a signal difference between a first signal and a second signal. The signal difference indicates a difference in an in vivo or in vitro pharmacological property. The first signal is produced upon binding between the target biomolecule and a first candidate by contacting the target biomolecule with the first candidate, and the second signal is produced upon binding between the target biomolecule and a second candidate by contacting the target biomolecule with the second candidate.